Want to see IPHA full AI Analyst Report?
IPHA Stock Chart & Stats
$1.66
-$0.03(-1.61%)
At close: 4:00 PM EST
$1.66
-$0.03(-1.61%)
Day’s Range― - ―
52-Week Range$1.17 - $2.63
Previous CloseN/A
Volume6.24K
Average Volume (3M)386.19K
Market Cap
$161.65M
Enterprise Value$150.19
Total Cash (Recent Filing)$34.30M
Total Debt (Recent Filing)$22.56M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Sep 17, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding93,921,860
10 Day Avg. Volume29,239
30 Day Avg. Volume386,189
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)-6.14
Price to Sales (P/S)47.79
P/FCF Ratio-3.81
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.50Price Target Upside291.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$36.26M
Bulls Say, Bears Say
Bulls Say
Regulatory Clearance And Designations For LacutamabFDA clearance for a Phase III protocol plus multiple expedited designations materially de-risks the registration pathway for lacutamab. These durable regulatory advantages shorten development timelines, increase partner and investor interest, and improve the odds of a viable commercialization strategy if clinical data confirm efficacy.
Material Partnership Milestone Potential With AstraZenecaLarge, structured milestones and prior upfront receipts from AstraZeneca provide a durable non-dilutive funding pathway tied to program progress. Such deal economics support R&D continuity, reduce execution risk from single-party funding, and align incentives for late-stage development and potential co-commercial strategies over the medium term.
Visible Cost Discipline And Reduced R&D SpendManagement has demonstrably reduced R&D expense and overall OpEx, reflecting disciplined allocation as programs mature. Sustained cost control improves runway management, prioritizes high-value studies, and lowers the pace of cash burn—an important structural improvement for a clinical-stage biotech reliant on milestone financing.
Bears Say
Tight Near-term Cash RunwayA runway only to end-Q3 2026 creates a persistent financing overhang that affects the timing of late-stage starts (e.g., TELLOMAK-3) and forces dependence on partnerships or capital markets. This structural funding constraint elevates execution risk, potential dilution, and the need for non-dilutive deals to sustain multi-program development.
Negative Shareholders' EquityNegative equity signals cumulative losses that materially weaken solvency and limit financial flexibility. Over a multi-month horizon this creates structural refinancing risk, reduces borrowing capacity, and increases the probability of dilutive capital raises or asset transactions to restore capitalization for ongoing clinical commitments.
Low Recurring Revenue Vs High Cash BurnA business model currently dominated by episodic collaboration receipts and grants cannot cover a consistent €60M+ OpEx profile. Persistent negative operating cash flow structurally forces reliance on milestone payments or financing, constraining long-term strategic optionality and the ability to self-fund multiple late‑stage programs simultaneously.
Innate Pharma News
IPHA FAQ
What was Innate Pharma’s price range in the past 12 months?
Innate Pharma lowest stock price was $1.17 and its highest was $2.63 in the past 12 months.
What is Innate Pharma’s market cap?
Innate Pharma’s market cap is $161.65M.
When is Innate Pharma’s upcoming earnings report date?
Innate Pharma’s upcoming earnings report date is Sep 17, 2026 which is in 58 days.
How were Innate Pharma’s earnings last quarter?
Innate Pharma released its earnings results on Mar 26, 2026. The company reported -$0.358 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.216.
Is Innate Pharma overvalued?
According to Wall Street analysts Innate Pharma’s price is currently Undervalued.
Does Innate Pharma pay dividends?
Innate Pharma does not currently pay dividends.
What is Innate Pharma’s EPS estimate?
Innate Pharma’s EPS estimate is -0.21.
How many shares outstanding does Innate Pharma have?
Innate Pharma has 93,921,860 shares outstanding.
What happened to Innate Pharma’s price movement after its last earnings report?
Innate Pharma reported an EPS of -$0.358 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -2.344%.
Which hedge fund is a major shareholder of Innate Pharma?
Currently, no hedge funds are holding shares in IPHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innate Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (291.57% Upside)
$6.50 (291.57% Upside)
Blogger Sentiment
Bullish
IPHA Sentiment 100%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-35.95%
Trailing 12-Months
Company Description
Innate Pharma
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
IPHA Stock 12 Month Forecast
Average Price Target
$6.50
▲(291.57% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.09% Other Institutional Investors
99.91% Public Companies and
Individual Investors